Parsonsmoon2769
To report our experience of treating painful C1 osteolytic lesions with cement augmentation via a lateral approach under fluoroscopic guidance.
Nine consecutive patients (eight men and one woman; mean age 56.7±13.2 years) with osteolytic lesions of the atlas who underwent cementoplasty via a lateral approach were enrolled in this study. The technical success rate, operation time, and complications were recorded. Visual analogue scale (VAS) and Neck disability index (NDI) were used to evaluate the pain relief and neck function status pre-procedure (baseline) and post-procedure (at 3 days; after 1, 3, 6, 12, 18, and 24 months; and at the last follow-up).
The procedure was technically successful without any complications in all patients. The mean procedure time was 44.3±7.8 min. There were three cases of bone cement leakage, but no clinical symptoms. The mean VAS score decreased from 6.7±1.0 before the procedure to 3.7 three days after the procedure. The mean NDI score decreased from 67.3±11.2 before the procedure to 39.3±13.7 three days after the procedure. The VAS and NDI scores decreased at each follow-up time point, and the difference was statistically significant compared with the scores before the procedure (P<0.01).
Fluoroscopy-guided lateral approach is a feasible, safe, and effective method for treatment of osteolytic lesions of the atlas and can relieve pain and stabilize the bone.
Fluoroscopy-guided lateral approach is a feasible, safe, and effective method for treatment of osteolytic lesions of the atlas and can relieve pain and stabilize the bone.
Sensory stimulation threshold (SST) has been used as a surrogate marker to target a nerve branch for radiofrequency (RF) denervation; however, the validity of SST as a prognostic marker is still under debate.
To assess whether lower SST values correlate with better outcomes of radiofrequency denervation for facetogenic low back pain.
Prospective cohort study.
Sixty-seven patients who underwent radiofrequency denervation for low back pain.
Correlations, between the average percentage of pain relief from diagnostic medial branch block (MBB) and RF denervation procedure outcome, and between SST and RF denervation procedure outcome, were analyzed using Spearman correlation coefficient (
). Wilcoxon rank sum test was performed to assess whether magnitude and duration of pain relief following RF denervation differed by the levels of SST (<0.5 and ≥0.5) or pain relief (<80% and ≥80%) from diagnostic MBB.
There was a positive correlation between pain relief after diagnostic MBB and pain relief 2 weeks after denervation (
0.31, 95% CI 0.08 to 0.51, p < 0.01), but not between pain relief after MBB and pain relief 6 months after denervation, nor pain relief duration after denervation. There was a negative correlation between SST and pain relief 6 months after denervation (
-0.41, 95% CI -0.59 to -0.18, p < 0.001). There was also a negative correlation between SST and pain relief duration after denervation (
-0.33, 95% CI -0.53 to -0.09, p < 0.01).
SST is a viable measurement with which to guide needle placement during RF denervation for lumbar facet pain, and enhances pain relief outcomes.
SST is a viable measurement with which to guide needle placement during RF denervation for lumbar facet pain, and enhances pain relief outcomes.[This corrects the article DOI 10.2147/JPR.S232132.].
The study was designed to mine the expression and roles of IQGAP3 in clear cell renal cell carcinoma (ccRCC).
Expression profiles and clinical information were obtained from the Cancer Genome Atlas (TCGA) to estimate IQGAP3 expression in ccRCC, its relationship with patients' clinicopathological variables and prognosis, and the potential biological mechanisms.
IQGAP3 was highly expressed in ccRCC and indicated advanced clinical outcome and poor prognosis. IQGAP3 affected the progression of ccRCC through several cancer-related pathways. IQGAP3 might play a vital role in the ccRCC tumor microenvironment.
IQGAP3 could serve as a promising prognostic biomarker and therapeutic target.
IQGAP3 could serve as a promising prognostic biomarker and therapeutic target.Hyperleukocytosis is a hematologic crisis caused by excessive proliferation of leukemic cells and has a relatively high early mortality due to a series of severe complications. Therefore, prompt and effective intervention is required. Leukapheresis performed using apheresis equipment to separate leukocytes from peripheral blood, at the same time returns autologous plasma, platelets and erythrocytes to the patient, is applied clinically for the treatment of hyperleukocytosis. Leukapheresis not only removes excessive leukocytes rapidly and corrects metabolic abnormalities but also alleviates the symptoms of leukostasis. In addition, the procedure of leukapheresis is generally well tolerated. Leukapheresis has become one of the most imperative adjuvant therapies to treat hyperleukocytosis, especially in the patient who was not inappropriate to cytoreduce with Ara-C or hydroxyurea. In this review, we present the background of leukapheresis development and highlight its clinical application in hyperleukocytic leukemia patients.
The present study aimed to explore the relationship between non-alcoholic fatty liver disease (NAFLD) and abdominal and pericardial adipose tissue in middle-aged and elderly subjects.
Between July 2019 and July 2020, 471 subjects attending the Health Care Medical Department of Peking Union Medical College Hospital for a medical examination were enrolled in the study. The volume and distribution of abdominal adipose tissue together with the volume of pericardial adipose tissue were calculated according to the results of the abdominal computed tomography. The differences between subjects with NAFLD and the normal population were analyzed.
The volume of pericardial adipose tissue, abdominal visceral and subcutaneous adipose tissue, the total volume of abdominal adipose tissue, and volume of pelvic visceral adipose tissue were all significantly increased in subjects with NAFLD. For every 100 cm
increase in the volume of abdominal visceral adipose tissue, the incidence of developing NAFLD increased by 9.4%. According to the results of the receiver operating curve, the cut-off point of abdominal visceral adipose tissue for the diagnosis of NAFLD was 2691.1 cm
.
Overall, the risk of NAFLD increases significantly with the increase in the volume of adipose tissue.
Overall, the risk of NAFLD increases significantly with the increase in the volume of adipose tissue.
To evaluate the effect of sublingual dust mite drops on inhaled corticosteroid replacement and its effect on asthma control level.
Two hundred children with asthma who had received regular treatment for one year or more were divided into the observation group (71 cases) and control group (89 cases) according to whether sublingual dust mite drops were added on the basis of conventional treatment drugs. After treatment, C-ACT score, VAS score, drug score, lung function, exhaled nitric oxide level, and "ICS avoidance" were compared between the two groups.
Before treatment, FVC and PEF25 scores in the observation group were lower than those in the control group, and the difference was statistically significant. There was no significant difference in other indicators between the two groups. There was no statistical significance in each index between the single allergic group and the multiple allergic group. Both the observation group and the control group showed statistically significant differences in each CS avoidance rate in the observation group was 57.4% (58/100), higher than that in the control group (17.0%, 17/100), and the difference was statistically significant (χ2=35.108, P < 0.01). The ICS avoidance rate was 55.6% (15/27) in the single allergic group and 58.1% (43/74) in the multiple allergic group, and there was no significant difference between the two groups (χ2=0.053, P=0.818).
Sublingual dust mite drops can significantly improve the asthma control levels in children with asthma and have the effect of inhaled corticosteroid replacement.
Sublingual dust mite drops can significantly improve the asthma control levels in children with asthma and have the effect of inhaled corticosteroid replacement.
We aimed to evaluate the impact of the COVID-19 pandemic on the knowledge and attitudes of patients among the Saudi population toward participating in clinical trials.
We conducted a descriptive, cross-sectional analysis using self-administered questionnaires for patients who attended the outpatient clinics at King Fahad Medical City and King Saud University Medical City in Riyadh, Saudi Arabia. The questionnaires included general questions about sociodemographic information, patient knowledge about clinical trials, and patient attitudes toward clinical trial participation. We used descriptive analysis to evaluate the impact of COVID-19 on patient knowledge and attitudes about clinical trials.
From November 2019 to October 2020, 822 responses were collected from participants in two medical cities and included in the analysis. Most of the study participants (81%) were younger than age 42 years. Our findings showed no difference between participants who participated in clinical trials before versus during the COVID-19 pandemic (P = 0.129).
The Saudi population knows about clinical trials, but they lack knowledge about the role of the ethics committee and about informed consent. Also, most of them do not have the experience of participating in a clinical trial. Still, they have moderately positive attitudes toward clinical trials.
The Saudi population knows about clinical trials, but they lack knowledge about the role of the ethics committee and about informed consent. Also, most of them do not have the experience of participating in a clinical trial. Still, they have moderately positive attitudes toward clinical trials.
To evaluate the changes of plasma levels of miR-126 in heart failure with a preserved ejection fraction (HFpEF) patients undergoing an exercise rehabilitation intervention.
miR-126 levels in plasma were compared between 60HFpEF patients and 30 healthy volunteers. HFpEF patients underwent exercise rehabilitation for 12 weeks. Before and after rehabilitation, indicators of cardiac function, exercise tolerance, quality of life scores and miR-126 levels were measured and compared. Correlations between plasma levels of miR-126 and HFpEF were evaluated.
The plasma levels of miR-126 in HFpEF patients were lower than those in healthy volunteers and increased significantly after exercise rehabilitation. HFpEF patients also showed significantly better cardiac function, exercise tolerance, and quality of life after rehabilitation. The results of Pearson correlation analysis and multiple linear regression showed that miR-126 levels were positively correlated with peak oxygen consumption (peak VO
) and metabolic equivalents (METs), and inversely associated with score on the Minnesota Living with Heart Failure Questionnaire (MLHF) as well as plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.
miR-126 levels are low expressed in plasma among HFpEF patients. Glutaraldehyde supplier Effective exercise rehabilitation in HFpEF patients may positively impact the plasma level of miR-126, which is probably associated with the restoration of cardiac function, exercise tolerance and quality of life. miR-126 may be a potential biomarker for evaluating the efficacy of exercise rehabilitation for HFpEF patients.
miR-126 levels are low expressed in plasma among HFpEF patients. Effective exercise rehabilitation in HFpEF patients may positively impact the plasma level of miR-126, which is probably associated with the restoration of cardiac function, exercise tolerance and quality of life. miR-126 may be a potential biomarker for evaluating the efficacy of exercise rehabilitation for HFpEF patients.
